Engineered immune cells take aim at Hard-to-Treat T-Cell cancers
NCT ID NCT07678307
First seen Jul 01, 2026 · Last updated Jul 01, 2026
Summary
This study tests a new treatment called nano CD5-CAR T cells for people with relapsed or refractory T-cell acute lymphoblastic leukemia or T-cell lymphoma. The therapy uses a patient's own immune cells, modified in a lab to recognize and attack cancer cells that carry the CD5 protein. The trial has two phases: the first checks safety and the best dose, and the second looks at how well the treatment works. Participants receive chemotherapy before a single infusion of the modified cells.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
autologous nano CD5-CAR T cells
What this could lead to
If it works, this could offer a new treatment option for people with hard-to-treat T-cell cancers that have not responded to standard therapy.
What could go wrong
This is an early-phase trial with only 18 participants, so results may not apply broadly. Risks include fever, low blood pressure, and infection, and the therapy may not work for everyone.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••